Literature DB >> 16730579

Sirolimus for Kaposi's sarcoma.

Cara A Wasywich1, Margaret C Croxson, Gerard J van Doornum, H Arthur Coverdale, Peter N Ruygrok.   

Abstract

The risk of Kaposi's sarcoma (KS) is increased after organ transplantation. Management of KS in the cardiac transplant population may be difficult because reduction of immunosuppression is often not practical. This report describes a case of KS occurring in the early post-transplant period. Modification of immunosuppression with the use of sirolimus led to tumor regression for 24 months, but with subsequent localized progression of disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16730579     DOI: 10.1016/j.healun.2006.01.010

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  4 in total

Review 1.  Immunosuppressive therapy in older cardiac transplant patients.

Authors:  Arezu Zejnab Aliabadi; Andreas Oliver Zuckermann; Michael Grimm
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

2.  Dual inhibition of PI3Kalpha and mTOR as an alternative treatment for Kaposi's sarcoma.

Authors:  Risa Chaisuparat; Jiadi Hu; Bruno C Jham; Zachary A Knight; Kevan M Shokat; Silvia Montaner
Journal:  Cancer Res       Date:  2008-10-15       Impact factor: 12.701

3.  Rapamycin blocks production of KSHV/HHV8: insights into the anti-tumor activity of an immunosuppressant drug.

Authors:  Lisa A Nichols; Laura A Adang; Dean H Kedes
Journal:  PLoS One       Date:  2011-01-14       Impact factor: 3.240

4.  Pulmonary Kaposi's sarcoma after heart transplantation: a case report.

Authors:  Florian R Fritzsche; Michaela Tutic; Isabelle Opitz; Roger Hunziker; Glen Kristiansen; Matteo Montani
Journal:  J Med Case Rep       Date:  2010-07-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.